Compare Nasdaq100 ETF (QQQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Viatris Inc — how do they compare? Nasdaq100 ETF trades at $707.5, while Viatris Inc trades at $17.45 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while Nasdaq100 ETF pays none, and Viatris Inc is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.
| QQQ | VTRS | |
|---|---|---|
52-Week High | $746.16 | $17.59 |
52-Week Low | $553.88 | $8.74 |
Market Cap | — | $20.50B |
Sector | — | Health |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $708.97, up 1.96% over the past 24 hours, with technical indicators signaling a bearish trend overall despite a neutral oscillator reading. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights institutional position adjustments and comparisons with competing tech-focused ETFs.
Outlook remains divided; potential exists from tech sector strength and AI-driven growth, but risks include high concentration in tech stocks and market volatility. Investors should weigh the bearish technical signals against long-term growth prospects in the Nasdaq-100 index.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
